SCHEMBL138887

SCHEMBL138887

Fc1ccc(C(F)(F)c2cc(Nc3nc4ccccc4s3)nc(Cl)n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 12/20 0.52
NPC1 O15118 11/20 0.52
SMN1; SMN2 Q16637 8/20 0.52
PIK3CG P48736 1/20 0.48
LCK P06239 4/20 0.47
ITK Q08881 4/20 0.47
AURKB Q96GD4 2/20 0.47
KDM4E B2RXH2 4/20 0.45
HTT P42858 2/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
LMNA P02545 3/20 0.43
MAPT P10636 6/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
GAA P10253 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL143889 0.86 LCK (0.49) RAB9ANPC1SMN1; SMN2LCKITK
SCHEMBL138176 0.84 LCK (0.55) RAB9ANPC1SMN1; SMN2LCKITK
SCHEMBL141486 0.84 LCK (0.67) RAB9ANPC1SMN1; SMN2LCKITK
SCHEMBL140569 0.83 PIK3CG (0.50) RAB9ANPC1SMN1; SMN2PIK3CGITK
SCHEMBL140313 0.81 LCK (0.55) RAB9ANPC1SMN1; SMN2LCKITK
SCHEMBL137557 0.78 ITK (0.77) RAB9ANPC1SMN1; SMN2LCKITK
SCHEMBL137558 0.78 ITK (0.77) RAB9ANPC1SMN1; SMN2LCKITK
SCHEMBL136247 0.78 LCK (0.67) RAB9ANPC1SMN1; SMN2LCKITK
SCHEMBL140467 0.73 DYRK1A (0.51) PIK3CGLCKITKAURKB
SCHEMBL4602494 0.70 NPC1 (1.00) RAB9ANPC1SMN1; SMN2PIK3CGKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS DTYMK, ITK, DCK RAB9A 3413/4885NPC1 2786/4885SMN1; SMN2 4393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.